Meet 2024 Ambassador Camden: A Legacy of Strength, Courage, and Resilience
Camden and his smile.
#CammersTough is more than just a hashtag. It represents the story of a boy who fought cancer with incredible strength and courage. His story of resilience in the face of continued hardship is what made him an inspiration to others.
Meet 2024 Ambassador Sam: A Renaissance Man with a Heart for Others
Sam playing the cello.
Twenty-year-old Sam is a Renaissance man – an accomplished musician, pilot, and philanthropist. He’s also a three-time shavee, childhood cancer survivor, and 2024 St. Baldrick’s Ambassador who is committed to making a difference in the lives of other kids with cancer.
Meet 2024 Ambassador Scott: A Childhood Cancer Survivor and Burgeoning Advocate
Ambassador Scott and the many pill bottles he went through during treatment.
Scott is a cheerful, hardworking 15-year-old who enjoys football, hanging out with friends, and traveling. His acute lymphoblastic leukemia (ALL) diagnosis at age 3 was a complete shock to his family, especially since he seemed healthy and never even had a sick visit to the pediatrician.
Since he was diagnosed as a toddler, he couldn’t fully understand that by the time he finished treatment 3 ½ years later, he would take more than 1,500 pills, have blood transfusions and countless spinal taps, unpleasant nebulized antibiotic treatments for immunosuppression, and spend more than half of his life on chemo.
Research Outcomes: Building Hope
Using Precision Medicine to Improve Pediatric Cancer Treatment
EXCITING UPDATE November 1, 2022: The largest academic collaboration of its kind was announced last month, and it builds off this St. Baldrick’s supported work. The Broad Institute of MIT and Harvard, Dana-Farber Cancer Institute and St. Jude Children’s Research Hospital will collaborate to transform and accelerate the identification of vulnerabilities in pediatric cancers and translate them into better treatments.
Dr. Stegmaier said, “The Pediatric Cancer Dependency Map provided our community with a treasure trove of new data. However, the next critical step was to validate candidate gene targets emerging from this project. The St. Baldrick’s Foundation Robert J Arceci Innovation Award provided the critical funding for us to demonstrate the power of the Pediatric Cancer Dependency Map.
With St. Baldrick’s support, we validated new candidate therapeutic targets in childhood cancers, such as Ewing sarcoma and neuroblastoma, which have led to the launching of drug discovery efforts, and we have gained novel insights into the mechanistic underpinnings of these diseases. We were able to show our community the power of the project. I think we are just at the tip of the iceberg. We are all very excited about the promise of what is to come through this new large-scale collaboration.”
We are excited to see the impact this collaboration has in helping to conquer childhood cancer.
2022 Ambassador – Meet Natasha, St. Baldrick’s First International Ambassador
2022 Ambassador: Meet Rocco – A 5-Year-Old Full of Love, Kindness, and Faith
The Top 2021 Messages Worth Remembering
As we close a difficult year, we reflect on lessons shared by childhood cancer patients and survivors who have faced adversity with grace, courage, and resilience. From their words, come some messages worth remembering now.
Sarah Swaim, age 31, two-time leukemia survivor & advocate
St. Baldrick’s Honored Kid, Sarah Swaim, and two-time leukemia survivor shares how having support during her cancer diagnosis helped her to keep going.What Is Acute Myeloid Leukemia (AML)?
Dr. Mizukawa is a past St. Baldrick’s Scholar. He explains acute myeloid leukemia symptoms, treatment, and research progress
What is acute myeloid leukemia (AML)?
Leukemia is cancer of the blood cells. Leukemia cells divide quickly and fail to mature into normal, functioning blood cells.
Acute leukemia progresses rapidly and is classified into two general subtypes:
- When the cancer affects the lymphocytes, a type of white blood cell, it is called acute lymphoblastic leukemia, or ALL.
- When the cancer affects other blood cell types, such as red blood cells, platelet-forming cells, and other types of white blood cells, it is called acute myeloid leukemia, or AML.
 Older Posts »